A Phase 3, Randomized, Double-Masked, Active-Controlled Trial of a Single Intravitreal Injection of 4D-150 in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration (4FRONT-2)

Condition studied

Macular neovascularization secondary to age-related macular degeneration (nAMD)

Investigational medicinal product(s)

Eligibility

Primary endpoint

Mean change from baseline in BCVA ETDRS letter score at Week 52

Endpoint detail

Mean annualized number of aflibercept injections after Week 4 through Weeks 52 and 104, Incidence and timing of aflibercept injections after Week 4 through Weeks 52 and 104, Proportion of subjects not requiring aflibercept injections after Week 4 through Weeks 52 and 104 in the 4D-150 arm, Time to first aflibercept injection after Week 4 in the 4D-150 arm, Mean change from baseline in CST over time through Weeks 52 and 104, Mean change from baseline in BCVA ETDRS letter score over time through Weeks 52 and 104